Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 8/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | IL6ST | P40189 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21447381 | 1.00 | NPC1 (0.44) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL16432228 | 0.92 | NPC1 (0.42) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL18627327 | 0.92 | NPC1 (0.42) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL16432226 | 0.92 | NPC1 (0.42) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL23699057 | 0.88 | HPGD (0.45) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL4684591 | 0.88 | HPGD (0.45) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL12634643 | 0.88 | HPGD (0.45) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL4684580 | 0.88 | HPGD (0.45) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL23699056 | 0.88 | HPGD (0.45) | NPC1LMNATP53HPGDRAB9A | |
| SCHEMBL21447357 | 0.88 | HPGD (0.45) | NPC1LMNATP53HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352316-B2 | Opioid receptor modulators and products and methods related thereto | EPIODYNE, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210163402-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2019195634-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352316-B2 | Opioid receptor modulators and products and methods related thereto | OPRM1, OPRD1, OPRK1 | NPC1 1812/4885LMNA 3394/4885TP53 4341/4885 |
| US-20210163402-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | OPRM1, OPRD1, OPRK1 | NPC1 1812/4885LMNA 3394/4885TP53 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.